Synthetic dosage-compensating miRNA circuits allow precision gene therapy for Rett syndrome

Area of Science:

• Molecular Biology
• Neuroscience
• Biotechnology

Background:

• Gene therapy requires precise control of dosage-sensitive genes like MECP2, mutations of which cause Rett syndrome.
• Viral gene delivery often results in variable gene copy numbers, complicating therapeutic approaches.
• Developing gene dosage-invariant expression systems is crucial for safe and effective gene therapy.

Approach:

• Engineered a compact miRNA-based incoherent feed-forward loop circuit for precise gene regulation.
• Utilized single-molecule analysis to confirm sustained and precise Mecp2 mRNA expression across varying gene dosages.
• Administered the systemically via an adeno-associated virus (AAV) vector with brain-targeting capsids in a mouse model.

Key Points:

• The miRNA-based circuit achieved precise and sustained control of Mecp2 expression in cells and brains.
• Gene therapy utilizing this circuit significantly improved behavioral outcomes in a Rett syndrome mouse model.
• Expression remained consistent across a wide range of gene delivery dosages.

Conclusions:

• Synthetic miRNA-based regulatory circuits offer a viable strategy for precise in vivo gene expression.
• This approach enhances the safety and efficacy of gene therapies for neurological disorders.
• The developed circuit outperformed unregulated gene therapy in a preclinical model.